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Abstract
Background: Airway eosinophilia is considered a central event in the pathogenesis of asthma. The
toxic components of eosinophils are thought to be important in inducing bronchial mucosal injury
and dysfunction. Previous studies have suggested an interaction between nitric oxide (NO) and
chemokines in modulating eosinophil functions, but this is still conflicting. In the present study, we
have carried out functional assays (adhesion and degranulation) and flow cytometry analysis of
adhesion molecules (VLA-4 and Mac-1 expression) to evaluate the interactions between NO and
CC-chemokines (eotaxin and RANTES) in human eosinophils.
Methods: Eosinophils were purified using a percoll gradient followed by immunomagnetic cell
separator. Cell adhesion and degranulation were evaluated by measuring eosinophil peroxidase
(EPO) activity, whereas expression of Mac-1 and VLA-4 was detected using flow cytometry.
Results: At 4 h incubation, both eotaxin (100 ng/ml) and RANTES (1000 ng/ml) increased by 133%
and 131% eosinophil adhesion, respectively. L-NAME alone (but not D-NAME) also increased the
eosinophil adhesion, but the co-incubation of L-NAME with eotaxin or RANTES did not further
affect the increased adhesion seen with chemokines alone. In addition, L-NAME alone (but not D-
NAME) caused a significant cell degranulation, but it did not affect the CC-chemokine-induced cell
degranulation. Incubation of eosinophils with eotaxin or RANTES, in absence or presence of L-
NAME, did not affect the expression of VLA-4 and Mac-1 on eosinophil surface. Eotaxin and
RANTES (100 ng/ml each) also failed to elevate the cyclic GMP levels above baseline in human
eosinophils.
Conclusion: Eotaxin and RANTES increase the eosinophil adhesion to fibronectin-coated plates
and promote cell degranulation by NO-independent mechanisms. The failure of CC-chemokines
to affect VLA-4 and Mac-1 expression suggests that changes in integrin function (avidity or affinity)
are rather involved in the enhanced adhesion.
Published: 12 August 2008
BMC Pulmonary Medicine 2008, 8:13 doi:10.1186/1471-2466-8-13
Received: 26 April 2008
Accepted: 12 August 2008
This article is available from: http://www.biomedcentral.com/1471-2466/8/13
© 2008 Lintomen et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Pulmonary Medicine 2008, 8:13 http://www.biomedcentral.com/1471-2466/8/13
Page 2 of 11
(page number not for citation purposes)
Background
Airway eosinophilia is considered a central event in the
pathogenesis of asthma. The toxic components of eosi-
nophils are thought to be important in inducing bron-
chial mucosal injury and dysfunction [1]. Evidences
suggest that recruitment of eosinophils into sites of
inflammation is a multifactorial and multistep process,
involving eosinophil-endothelial interactions through
adhesion molecules and local generation of chemotactic
agents that direct cell migration into the inflamed airways
[2]. Thus, adhesion molecules and chemokines play key
roles in selective eosinophil accumulation [3]. The
integrins macrophage adhesion molecule-1 (Mac-1,
CD11b/CD18,  αMβ2) and very late antigen-4 (VLA-4,
CD49d/CD29, α4β1) are the most important integrins
responsible for the firm adhesion of eosinophils to the
endothelium through their ligands the intercellular adhe-
sion molecule (ICAM)-1 and the vascular cell adhesion
molecule (VCAM)-1 [4]. The integrin VLA-4 is constitu-
tively expressed in eosinophils [5], whereas Mac-1 is
expressed in eosinophils stimulated with different class of
mediators such as platelet-activating factor (PAF), granu-
locyte macrophage colony stimulating factor (GM-CSF),
and N-formyl-methionyl-leucyl-phenylalanine (fMLP) [6-
8]. Both Mac-1 and VLA-4 integrins have a role in the
degranulation and superoxide anion production in stim-
ulated eosinophils [6,9], and thus can also be referred as
mediators of eosinophil functions. These integrins can
also bind to extracellular matrix components such as
serum, fibrinogen and fibronectin. Adhesion of eosi-
nophils to fibronectin via VLA-4 [8] prolongs cell survival
by Fas antigen signalling, indicating a role for integrin
adhesion and signaling in regulating eosinophil function
and death [10]. The firm adhesion of eosinophils to
fibronectin is mediated through the binding of eosi-
nophil-expressed VLA-4 to the connecting segment 1 (CS-
1) region of fibronectin. Eosinophils bind to CS-1 with
high avidity, an effect inhibited with neutralizing antibod-
ies to α4 integrins expressed by eosinophils or with neu-
tralizing antibodies to CS-1 [11].
Eotaxin and RANTES (Regulated upon activation normal
T cell expressed and secreted) are CC-chemokines respon-
sible for selective eosinophil chemotaxis and transend-
othelial migration in airways of allergic subjects [12-15].
Selective activation of VLA-4 by eotaxin has provided one
mechanism of more efficient recruitment of eosinophils
to the lung [16]. In addition, eosinophil priming with
interleukin-5 (IL-5) results in a synergistic increase in
transendothelial migration in response to RANTES [17]
and eotaxin [18]. In fact, interactions of IL-5 and chemok-
ines induce a change in the affinity of VLA-4 in respond-
ing leukocytes [5].
Several studies have demonstrated the involvement of
nitric oxide (NO) on eosinophil recruitment, but this is
still a matter of controversy. Rats treated with the nitric
oxide synthase (NOS) inhibitor Nω-nitro-L-arginine
methyl ester (L-NAME) shows a marked reduction in rat
eosinophil migration in vivo in an allergic inflammation
model [19]. In vitro studies have showed that incubation
of rat or human eosinophils with NOS inhibitors attenu-
ate the in vitro chemotaxis, suggesting that NO has a role
in cell locomotion [20,21]. Previous studies have investi-
gated the functional interactions between NO and CC-
chemokines. Young et al. [22] showed that increased
number of eosinophils in bronchoalveolar lavage (BAL)
fluid of challenged monkeys is markedly increased at 24 h
post-challenge, and that is accompanied by higher levels
of both exhaled NO and eotaxin in BAL fluid. In rhinitis
patients, eotaxin increased the number of eosinophils in
the nasal lavage fluid, and that was also accompanied by
elevated nasal NO levels [23]. In contrast, in murine mod-
els of asthma, selective inhibition of inducible NOS
resulted in reduction of the pulmonary eosinophil migra-
tion [24,25], which was associated with increased expres-
sion of the CC-chemokine monocyte chemoattractant
protein-1 (MCP-1) in the lung tissue [26]. Moreover, NO
(or NO donors) have also been shown to inhibit the pro-
duction of RANTES [27]. Nitric oxide via peroxynitrite
(ONOO-) formation was also shown to reduce the
eotaxin-induced eosinophil migration [28]. However, the
modulatory role of NO in the CC-chemokines-mediated
eosinophil functions is still conflicting. Therefore, the
present study was designed to investigate the modulatory
effect of NO in the enhanced eosinophil adhesion and
degranulation induced by the CC-chemokines eotaxin
and RANTES in vitro, and the expression of VLA-4 and
Mac-1 in the eosinophil surface.
Methods
Human eosinophil isolation
Blood was collected from healthy volunteers who were
not under medication. Informed consent and approval
from the local ethics committee were obtained before the
study. Eosinophils were isolated from peripheral blood as
originally described by Hansel et al. [29] with minor mod-
ifications. Briefly, 60–120 ml of blood collected in 3.13%
(w/v) sodium citrate was diluted 1:1 with phosphate buff-
ered saline (PBS) and 35 ml of diluted blood was overlaid
onto a 15 ml Percoll gradient (1,088 g/ml, pH 7.4, 340
mosmol/Kg H2O). Gradients were centrifuged at 1000 × g
for 20 min, 4°C (Hermle model Z360k centrifuge, Ger-
many) and the pellet containing red cells and granulo-
cytes was collected. Red cells were lysed with lysing buffer
(155 mM NH4Cl, 10 mM KHCO3 0.1 mM EDTA), and
the remaining granulocytes were washed and then incu-
bated with anti-CD16 immunomagnetic microbeads for
30 min before passing on a steel-matrix column in a mag-BMC Pulmonary Medicine 2008, 8:13 http://www.biomedcentral.com/1471-2466/8/13
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netic field and CD16-negative eosinophils were collected.
Eosinophils were resuspended in RPMI-1640 medium
(without phenol red), pH 7.2 (> 92% eosinophils, con-
taminating cells were mononuclear cells).
Experimental Protocols
After the purification of human isolated eosinophils, the
following in vitro assays were carried out: cell viability
(MTT assay), adhesion to fibronectin-coated plates, EPO
release (cell degranulation), cGMP level measurement
and flow cytometry analysis for the adhesion molecules
VLA-4 and Mac-1. These assays have been performed in
eosinophils stimulated with either eotaxin or RANTES, in
the absence and/or in the presence of L-NAME, as detailed
below.
MTT assay
Cell viability was estimated using the tetrazolium salt
reduction test (MTT assay) by eosinophils after exposure
to chemokines. Isolated eosinophils were resuspended to
a concentration of 2 × 106 cells/ml in RPMI-1640 medium
(without phenol red) and then were exposed or not to
eotaxin or RANTES (10, 100 and 1000 ng/ml each) for 2,
3 or 4 h at 37°C in a humified atmosphere. Eosinophils
(100 μl/well), treated or not, and 3-(4,5-dimethylthiazol-
2-yl)-2,5 diphenyl tetrazolium bromide (MTT, 10 μl/well,
5 mg/ml in PBS) were added in triplicate to a 96-well
plates. Cells were allowed to incubate for 3 h at 37°C and
5% CO2. After incubation, 100 μl of 10% SDS in 0.01 M
HCl was added to each well. Cell samples were then incu-
bated for 18 h at 37°C, 5% CO2 and absorbance meas-
ured at 540 nm in a microplate reader (Multiscan MS,
Labsystems, USA).
Eosinophil adhesion assay
96-well plates were prepared by coating individual wells
with 60 μl of fibronectin solution (20 μg/ml in PBS) over-
night at 4°C. Wells were then washed twice with PBS
before blocking non-coated sites with 0.1% (w/v) BSA for
60 min at 37°C. Wells were washed twice again with PBS
before allowing plates to dry. Eosinophils (50 μL of 7 ×
104 cells/ml) were incubated with either eotaxin (10–
1000 ng/ml) or RANTES (10–1000 ng/ml) for 2, 3 and 4
h in the absence or in the presence of 0.1 mM of L-NAME
(or its inactive enantiomer D-NAME) prior to addition to
fibronectin-coated wells. Platelet-activating factor (PAF;
10-6 M) was used as a positive control [30]. After 2, 3 or 4
h of incubation, the eosinophils were added in a volume
of 50 μl of RPMI-1640 medium without phenol red (7 ×
104 cells/ml) to the coated wells. Cells were allowed to
adhere to wells for 30 min at 37°C, 5% CO2. After incu-
bation, non-adhered cells were removed and the remain-
ing cells were washed twice with PBS. Fifty μl of RPMI-
1640 medium were added to each well, and varying con-
centrations of the original cell suspension were added to
empty wells to form a standard curve. Eosinophil adhe-
sion was calculated by measuring residual eosinophil per-
oxidase (EPO) activity of adherent cells [9]. Fifty μl of
EPO substrate (1 mM H2O2, 1 mM o-phenylenediamine
and 0.1% Triton X-100 in Tris buffer, pH 8.0) were added
to each well. After 30 min at room temperature, 25 μl of 4
M H2SO4 were added to each well to stop the reaction
and absorbance measured at 490 nm in a microplate
reader. Adherence was calculated by comparing absorb-
ance of unknowns to that of the standard curve. In order
to exclude the possibility that enhanced eosinophil adhe-
sion to chemokines or L-NAME reflects augmented EPO
activity, varying number of eosinophils (20 to 200 μL of 7
× 104cells/ml) were incubated with RPMI alone, eotaxin
(100 ng/ml), RANTES (100 ng/ml) or L-NAME (0.1 mM)
4 h in non-coated wells. The EPO measurement in all
samples did not differ significantly among each other in
any condition used (data not shown), indicating that EPO
activity can be used as a marker of eosinophil adhesion.
Each experiment was carried out in triplicate (n = 6 differ-
ent individuals).
Eosinophil degranulation assay
Eosinophil peroxidase release was measured in the super-
natants by the o-phenylenediamine (OPD) method [31].
All tubes used were precoated with 2.5% human serum
albumin for 2 h at 37°C to block nonspecific activation of
eosinophils, and were washed with 1 ml of PBS once
before aliquots of eosinophils were added. Ninety μl of
eosinophils (5 × 106  cells/ml in RPMI-1640 medium
without phenol red) stimulated or not with eotaxin (100
ng/ml) or RANTES (100 ng/ml), in the absence or in the
presence of 0.1 mM of L-NAME (or of 0.1 mM D-NAME),
were incubated for 4 h at 37°C, 5% CO2. The calcium
ionophore A23187 (5 μM, 30 min) was used as a positive
control [32]. At the end of the incubation period the reac-
tion was stopped by cooling on ice for 3 min. The samples
were centrifuged at 250 × g for 15 min at 4°C and the cells
discarded. Aliquots of the supernatants (50 μl; triplicate)
were dispensed into each well of a microplate, and 50 μl
of eosinophil peroxidase substrate (1 mM H2O2, 1 mM
OPD and 0.1% Triton X-100 in Tris buffer, pH 8.0) was
added to each well. Measurement of EPO activity was
measured at 490 nm using a microplate reader (Multiscan
MS, Labsystems, USA), as described above. Each experi-
ment was carried out in triplicate (n = 4 different individ-
uals).
Flow cytometry
Eosinophils were incubated with either eotaxin (100 ng/
ml) or RANTES (100 ng/ml) for 4 h in the absence and/or
in the presence of L-NAME. Eosinophils were also incu-
bated with PAF (10-6 M) using the same experimental con-
ditions. Expression of adhesion molecules on the surface
of eosinophils was detected using flow cytometry. After 2,BMC Pulmonary Medicine 2008, 8:13 http://www.biomedcentral.com/1471-2466/8/13
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3 or 4 h of incubation, eosinophils were washed and incu-
bated (100 μL of 3 × 106 cells/ml) for 20 min at 4°C with
5 μl of human serum. Cells were washed and incubated
for 20 min at 4°C with 5 μl of RPE-conjugated mouse
IgG1, k monoclonal immunoglobulin isotype control,
RPE-conjugated mouse anti-human CD11b/Mac-1 mono-
clonal antibody or RPE-conjugated anti-human CD49d
monoclonal antibody, after which they were washed and
fixed in 0.3 ml 0.5% paraformaldehyde. Cells were ana-
lysed on a Becton-Dickinson FACScalibur (San Jose,
USA). The mean fluorescence intensity was compared to
that of isotype control reacted cells.
Extraction and measurement of cyclic guanosine-3', 5'-
monophosphate (cGMP) from eosinophils
Eosinophils were isolated and resuspended to a concen-
tration of 1 × 107 cells/ml in PBS. Cells were incubated
with the phosphodiesterase inhibitor 3-isobutyl-l-methyl-
xanthine (IBMX; 2 mM) for 30 min at room temperature.
Then, eosinophils were incubated (37°C, humidified
atmosphere) for 30 min or 4 h with or without eotaxin (or
RANTES) and/or L-NAME. The NO donor sodium nitro-
prusside (SNP; 0.1 mM) were used as positive control in
the cGMP assays. Next, the reaction was interrupted by the
addition of cold acidified absolute ethanol to a final con-
centration of 67% (v/v), and samples were vigorously agi-
tated by hand for 30 sec. Cell samples were then
incubated on ice for 30 min before centrifuging at 4000 g
for 30 min at 4°C. The supernatants were collected,
retained and the precipitates washed with 0.5 ml 67% (v/
v) acidified ethanol before centrifuging again at 14,000 g
for 5 min at room temperature. The supernatants from
these washed samples were collected and added to the
first supernatants collected and dried at 55–60°C under a
stream of nitrogen in a water bath and stored at -20°C
until measurement of cGMP. Cyclic GMP in 1.5 × 106
cells/well was measured using Cayman kit (Ann Arbor,
USA). The samples for measurement of cGMP were previ-
ously acetylated, following the manufacturer recommen-
dations. Each experiment was carried out in triplicate
using 03 healthy volunteers.
Materials
The system used for eosinophil purification, complete
with columns and microbeads, was acquired from
Miltenyi Biotec Inc. (Auburn, CA, USA). The antibodies
used to flow cytometry assays were purchased from BD
Biosciences Pharmingen (RPE-conjugated mouse IgG1, k
monoclonal immunoglobulin isotype control, RPE-con-
jugated mouse antihuman CD11b/Mac-1 monoclonal
antibody and RPE-conjugated anti-human CD49d mono-
clonal antibody; San Jose, USA). Recombinant human
eotaxin and RANTES were obtained from R&D Systems
(Saint Louis, USA). All other products were purchased
from Sigma Chem. Co (St. Louis, MO, USA), unless oth-
erwise stated.
Statistical analysis
Results are expressed as means ± S.E.M and analysis of var-
iance (ANOVA) for multiple comparisons followed by
Tukey's test, or unpaired Student's t-test were performed
when appropriate. A value of P < 0.05 was taken as signif-
icant.
Results
Cell viability
The MTT reduction assay was performed to ascertain the
eosinophil viability during incubation periods of 2, 3 and
4 h in the presence of either eotaxin or RANTES (10–1000
ng/ml). Our data showed that eosinophils remained via-
ble in all concentrations and incubation periods studied
(Table 1). A concentration-dependent increase (P < 0.05)
in cell activity was rather detected in most of our experi-
mental conditions.
Eotaxin and RANTES-induced eosinophil adhesion to 
fibronectin
Eosinophils (50 μL of 7 × 104 cells/ml) were incubated
with either eotaxin (10–1000 ng/ml) or RANTES (10–
1000 ng/ml) for 2, 3 and 4 h prior to addition to fibronec-
tin-coated wells. At 2 and 3 h incubation, neither eotaxin
nor RANTES significantly increased the eosinophil adhe-
sion to fibronectin in comparison with non-stimulated
cells (not shown; n = 6 each). On the other hand, at 4 h
incubation, eotaxin and RANTES significantly (P < 0.05)
increased the eosinophil adhesion compared with non-
stimulated cells (Figure 1). Maximal eosinophil adhesion
to eotaxin (14.1 ± 2.2%) and RANTES (13.9 ± 2.1%) was
observed with the concentration of 100 ng/ml of each. In
the same experimental conditions, incubation of eosi-
nophils with PAF (10-6 M), used as a positive control, sig-
Table 1: MTT reduction assay in stimulated eosinophils in vitro.
Treatment MTT Reduction (% control)
2  h3  h4  h
Eotaxin
(10 ng/ml) 84.6 ± 6.6 113.0 ± 6.1 91.0 ± 2.7
(100 ng/ml) 113.8 ± 5.0* 130.7 ± 2.3* 127.3 ± 3.6*
(1000 ng/ml) 124.7 ± 5.0* 138.4 ± 2.0* 146.0 ± 11.8*
RANTES
(10 ng/ml) 104.8 ± 1.6 128.8 ± 8.0* 105.8 ± 1.0
(100 ng/ml) 118.9 ± 2.8* 133.4 ± 3.6* 138.4 ± 6.0*
(1000 ng/ml) 117.4 ± 3.8* 118.0 ± 1.0* 147.0 ± 6.9*
Eosinophil suspension (2 × 106cells/ml) was incubated for 2, 3 or 4 h 
with eotaxin (10–1000 ng/ml) or RANTES (10–1000 ng/ml). Each 
experiment was carried out in triplicate (n = 3). Results are expressed 
as MTT reduction (% control). *P < 0.05 compared to respective 
untreated cells.BMC Pulmonary Medicine 2008, 8:13 http://www.biomedcentral.com/1471-2466/8/13
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nificantly increased the eosinophil adhesion (12.8 ±
2.0%; Figure 1). For further experiments, the time of 4 h,
and chemokine concentrations of 100 ng/ml were chosen
as best incubation period and optimum concentrations.
Figure 2 shows that incubation of eosinophils with L-
NAME alone (0.1 mM) increased significantly the adhe-
sion of eosinophils to fibronectin (10.4 ± 1.6%; P < 0.05)
compared with non-stimulated cells (6.2 ± 1.2%),
whereas its inactive enantiomer D-NAME (0.1 mM) had
no effect (6.3 ± 0.3%). However, co-incubation of L-
NAME with eotaxin or RANTES did not affect the
increased adhesion seen with the chemokines alone (Fig-
ure 2).
Eotaxin and RANTES-induced eosinophil degranulation
Table 2 shows that incubation of human eosinophils (90
μL of 5 × 106 cells/ml) with either eotaxin (100 ng/ml) or
RANTES (100 ng/ml) caused a significant cell degranula-
tion (P < 0.001) in comparison with basal response. Incu-
bation of eosinophils with 0.1 mM of L-NAME alone (but
not with the inactive enantiomer D-NAME) also increased
significantly (P < 0.001) cell degranulation when com-
pared with non-stimulated cells. Co-incubation of L-
NAME with either eotaxin or RANTES did not further
affect the increased degranulation seen with the chemok-
ines alone (Table 2). Using the same experimental condi-
tions, the calcium ionophore A23187 (5 μM), used as a
positive control, increased by 135% the EPO release
above basal values.
Expression of integrins in human eosinophils
Expression of α4 (CD49d) and αM (CD11b/Mac-1) sub-
units on the eosinophil surface was determined by fluo-
rescent-immunolabelling cells and detection by flow
cytometry. Eosinophils, treated or not with either eotaxin
or RANTES during 4 h, were incubated with the respective
monoclonal antibodies, and the average mean fluores-
cence were detected by flow cytometry. Neither eotaxin
(100 ng/ml) nor RANTES (100 ng/ml) affected the expres-
sion of α4 (Figure 3A) or αM subunits (Figure 3B) on eosi-
nophils in any of the incubation periods.
Adhesion of human eosinophils to fibronectin-coated plates Figure 1
Adhesion of human eosinophils to fibronectin-coated plates. Eosinophils (3.5 × 103cells/well) were incubated with 
eotaxin (10, 100 and 1000 ng/ml), RANTES (10, 100 and 1000 ng/ml) or platelet-activating factor (PAF; 10-6 M) for 4 h (37°C, 
5%CO2) and then allowed to adhere to fibronectin-coated wells for 30 min. Results are expressed as mean adhered cell per-
centages of total cell number ± SEM (n = 6). * P < 0.05 compared to control (CTRL).
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To verify the effect of L-NAME upon integrin expression of
chemokine-stimulated and non-stimulated, eosinophils
were incubated for 4 h with L-NAME alone or in the pres-
ence of eotaxin (or RANTES). No changes were detected in
the expression of α4 or αM subunits (Figure 3A,B).
In eosinophils treated with PAF (10-6 M; used as a positive
control) an increase in the αM expression about of 20%
was found (fluorescence intensity of 234.1 ± 19.8) com-
pared with untreated cells (fluorescence intensity of 196.9
± 9.6; Figure 3B).
Effect of chemokines and L-NAME upon intracellular 
cGMP levels in eosinophils
Incubation of eosinophils for either 30 min or 4 h with
eotaxin (100 ng/ml) did not significantly increase the
concentration of cyclic cGMP (2.9 ± 0.5 and 4.2 ± 0.5
pmol/ml, respectively) above baseline (2.3 ± 0.3 and 4.4
± 0.5 pmol/ml, respectively; n = 3). Incubation of eosi-
nophils with eotaxin (100 ng/ml each) in the presence of
L-NAME (0.1 mM) also failed to affect the cGMP produc-
tion (2.7 ± 0.2 and 4.3 ± 0.4 pmol/ml, for 30 min and 4
h-incubation, respectively; n = 3).
RANTES (100 ng/ml) also failed to significantly increase
the cGMP levels above baseline (2.6 ± 0.4 and 4.5 ± 0.6
pmol/ml, respectively, for 30 min and 4 h incubation,
respectively). Incubation of eosinophils with RANTES
(100 ng/ml each) in the presence of L-NAME (0.1 mM)
also failed to affect the cGMP production (2.1 ± 0.2 and
4.2 ± 0.4 pmol/ml, for 30 min and 4 h-incubation, respec-
tively; n = 3).
Incubation of eosinophils with the NO-donor SNP (0.1
mM; positive control) markedly increased (P < 0.001) the
cGMP levels above baseline at 30 min and 4 h (7.7 ± 0.7
and 6.2 ± 0.5 pmol/ml, respectively).
Discussion
The roles of chemokines and NO in eosinophil functions
in allergic processes have been largely studied, but studies
focusing on the interaction between CC-chemokines (par-
ticularly eotaxin and RANTES) and the NO-cGMP path-
way have been poorly explored. In the present study,
using human eosinophils in vitro, our findings are clear to
suggest that NO modulates neither the enhanced adhe-
sion and degranulation in response to eotaxin or RANTES,
Lack of effect of Nω-nitro-L-arginine methyl ester (L-NAME) upon eotaxin- and RANTES-induced eosinophil adhesion to  fibronectin-coated plates Figure 2
Lack of effect of Nω-nitro-L-arginine methyl ester (L-NAME) upon eotaxin- and RANTES-induced eosinophil 
adhesion to fibronectin-coated plates. Eosinophils (3.5 × 103 cells/well) were incubated with platelet-activating factor 
(PAF; 10-6M), D-NAME; 0.1 mM), L-NAME (0.1 mM), eotaxin (EOT; 100 ng/ml) or RANTES (RAN; 100 ng/ml) for 4 h (37°C, 
5%CO2), and then allowed to adhere to fibronectin-coated wells for 30 min. Results are expressed as mean adhered cell per-
centages of total cell number ± SEM (n = 6). * P < 0.05 compared to control (CTRL).
0
10
20
* *
*
***
          CTRL     PAF   D-NAME  L-NAME   EOT      RAN       EOT     RAN
                                                                                        +  L-NAME
%
 
a
d
h
e
s
i
o
nBMC Pulmonary Medicine 2008, 8:13 http://www.biomedcentral.com/1471-2466/8/13
Page 7 of 11
(page number not for citation purposes)
nor the Mac-1 and VLA-4 expression in the eosinophil sur-
face.
Among the eosinophil-active chemoattractants described
to date, the CC-chemokines, particularly RANTES,
eotaxin, eotaxin-2, MCP-3 and MCP-4 have been sug-
gested to contribute to bronchial eosinophilia in patients
with asthma [33,34]. In general, chemokines can induce
integrin expression on the surface of leucocytes, allowing
firm adhesion to the endothelium near to the inflamed
focus [35], and then stimulating the transendothelial
migration [36]. In murine eosinophils of IL-5 transgenic
mice, eotaxin increases the CD11b and VLA-4 expressions,
with maximal responses observed 1 h (CD11b) and 2 h
(VLA-4) after incubation with eotaxin, suggesting that
Mac-1/ICAM-1 interactions are dominant at early time,
whereas VLA-4/VCAM-1 becomes predominant at later
time-points during eotaxin-induced eosinophil recruit-
ment [37]. In human eosinophils, a flow cytometry study
showed that 15 min-incubation with eotaxin (300 ng/ml)
caused increased surface expression of CD11b [38]. In an
apparent contrast with this work, our present study
showed that the CD49d and CD11b expression in human
eosinophils incubated with eotaxin remained unchanged
in all incubation periods studied. This discrepancy could
reflect differences in the animal species (IL-5-transgenic
mice vs human) and source of eosinophils used (perito-
neal vs peripheral blood), as well as incubation-time used
(30 min vs 4 h). On the other hand, a previous study also
failed to demonstrate an increased expression of α4
integrin in human eosinophils treated for 30 min with
eotaxin [11]. Similarly, our data from RANTES-stimulated
eosinophils demonstrated no change on expression of
CD49d or CD11b, which are in accordance with Jia et al.
[37] in murine eosinophils. Additionally, in human eosi-
nophils in vitro RANTES was shown to induce transend-
othelial migration without affecting the CD11b
expression [17].
The action of NO is generally carried out through the acti-
vation of the soluble guanylyl cyclase, thereby increasing
intracellular levels of cGMP, which acts as its second mes-
senger. This signal transduction pathway underlies the
majority of physiological actions attributed to NO,
including regulation of leukocyte rolling, adhesion, and
extravasation [39,40]. Immunohistochemical studies
revealed that rat and human eosinophils express induci-
ble and endothelial NO synthases, and activated rat peri-
toneal eosinophils are able to release NO [20,41].
Furthermore, the NO synthesis inhibitor L-NAME reduces
the experimental eosinophil migration in vivo, suggesting
a fundamental role for NO in eosinophil chemotactic
responses [19,24] that has been associated with increased
expression of MCP-1 and MIP-2 in the lung tissue [26].
On the other hand, L-NAME has been shown to enhance
the in vivo cat leukocyte adhesion and the human eosi-
nophil adhesion to fibronectin-coated plates [8,40]. How-
ever, no study exists investigating a potential role of NO-
cGMP signaling pathways modulating the enhanced eosi-
nophil adhesion in response to CC-chemokines. In the
present study, at 4 h-incubation time, L-NAME itself
increased the eosinophil adhesion, confirming a previous
study [8]; however, L-NAME failed to affect the enhanced
adhesion in response to both eotaxin and RANTES. Both
of these CC-chemokines also failed to elevate the cGMP
concentrations above the baseline. Additionally, treat-
ment of eosinophils with L-NAME alone or in combina-
tion with eotaxin (or RANTES) had no effect in the cell
integrin expressions (αM or α4 subunits), all suggesting
that CC-chemokines eotaxin and RANTES increases the in
vitro eosinophil adhesion to fibronectin-coated plates by
NO-independent mechanisms. It is known that Granulo-
cyte-macrophage colony-stimulating factor (GM-CSF) up-
regulates the binding of eosinophils to VCAM-1 or
fibronectin (CS-1 region) by up-regulating the binding
affinity of VLA-4 to VCAM-1 (or to CS-1), which is not
associated with changes in the integrin expression [11].
The binding of eosinophils to CS-1 is inhibited with neu-
tralizing antibodies to α4 integrins expressed by eosi-
nophils or with neutralizing antibodies to CS-1 [11].
Moreover, in the presence of eotaxin, a transient increase
in the force of eosinophil adhesion to CS-1 is followed by
a sustained reduction in the force of eosinophil adhesion
to CS-1. This latter phase was not due to alterations in
VLA-4 receptor number or alterations in VLA-4 receptor
distribution [11]. This suggested to authors that confor-
mational changes in VLA-4 receptor may be responsible
for the change in binding affinity. In our study, whether
such mechanism operates in L-NAME- and CC-chemok-
ines-treated human eosinophils requires additional stud-
ies. We also would like to emphasize that a small fraction
Table 2: Effect of L-NAME and CC-chemokines upon eosinophil 
peroxidase (EPO) release.
Treatment Optical density
CTRL 0.39 ± 0.02
A23187 (5 μM) 0.87 ± 0.04*
D-NAME (0.1 mM) 0.27 ± 0.01
L-NAME (0.1 mM) 0.70 ± 0.04*
Eotaxin (100 ng/ml) 0.70 ± 0.03*
RANTES (100 ng/ml) 0.71 ± 0.05*
Eotaxin+L-NAME 0.77 ± 0.02*
RANTES+L-NAME 0.69 ± 0.04*
Eosinophils (4.5 × 105 cells) were incubated or not (CTRL) with Nω-
nitro-L-arginine methyl ester (L-NAME; 0.1 mM), eotaxin (100 ng/ml) 
or RANTES (100 ng/ml) for 4 h (37°C, 5%CO2). After incubation the 
released peroxidase in 50 μl of supernatant was measured and 
expressed as mean ± SEM of optical density (n = 4). *P < 0.05 
compared to control (CTRL).BMC Pulmonary Medicine 2008, 8:13 http://www.biomedcentral.com/1471-2466/8/13
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Effect of L-NAME and CC-chemokines upon eosinophil expression of α4 and αM subunits Figure 3
Effect of L-NAME and CC-chemokines upon eosinophil expression of α4 and αM subunits. Eosinophils (3.0 × 105 
cells) were incubated or not (CTRL) with platelet-activating factor (PAF; 10-6M), Nω-nitro-L-arginine methyl ester (L-NAME; 
0.1 mM), eotaxin (EOT; 100 ng/ml) or RANTES (RAN; 100 ng/ml) for 4 h (37°C, 5%CO2), and then were labelled with anti-α 4 
(VLA-4; Panel A) or anti-αM (Mac-1; Panel B) antibodies. The results are expressed as mean fluorescence ± SEM (n = 4).
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of stimulated cells were able to adhere, which seems to be
a common feature of in vitro models exploring cell adhe-
sion. The basal (non-stimulated) adhesion in models of
serum-, fibrinogen-, fibronectin- or recombinant VCAM1-
coated wells ranges always from 5 to 30%, depending of
the cell type used (eosinophils, neutrophils, platelets) and
experimental conditions [8,42-46]. Most importantly, cell
stimulation with different agents usually enhances the
adhesion about of 20–100% above baseline.
Eotaxin and RANTES are also important chemotactic fac-
tors for eosinophils, and are reported to largely contribute
to the movement of eosinophils from the blood to the
sites of inflammation. Once recruited to tissues, eosi-
nophils receive signals to promote degranulation, causing
the release of eosinophil granule proteins such as major
basic protein (MBP), eosinophil peroxidase (EPO) and
eosinophil cationic protein (ECP) that has been associ-
ated with the induction of epithelial damage, edema, and
airways hyperreactivity, playing therefore a pivotal role in
the pathogenesis of allergic disorders [47]. Accordingly,
the increased presence of cationic granule in the asthmatic
lung correlates with severity of bronchial asthma [48,49].
Amongst the inflammatory mediators postulated to con-
tribute to eosinophil degranulation, eotaxin and/or
RANTES have been shown to release CCR3-dependent
granule proteins [50,51] in equivalent amounts to PAF,
which is considered a potent eosinophil activator [52]. In
a human eosinophil cell line (15-HL-60), eotaxin,
eotaxin-2 and eotaxin-3 also produced concentration-
dependent degranulation of EPO [53]. Since the chemok-
ines may reach high amounts in the allergic inflammatory
site, it is accepted that they greatly contribute to local eosi-
nophil degranulation [52]. Our findings showed that
both eotaxin and RANTES caused a significant eosinophil
degranulation, thus confirming the literature data. How-
ever, the failure of L-NAME to modify the eotaxin- and
RANTES-induced degranulation indicates that NO does
not modulate degranulation in CC-chemokine-activated
eosinophils. It is interestingly, however, that L-NAME
itself significantly increased the EPO release in equivalent
amounts to the CC-chemokines. While in other cell types
such as mast cells, NO synthesis inhibitors are reported to
cause cell degranulation [54,55], to our understanding the
present study is the first to show that in vitro NO inhibi-
tion in human eosinophils leads to cell degranulation. It
is known that exocytosis of stored granule proteins of
eosinophils takes place by three distinct mechanisms,
namely classical exocytosis, piecemeal degranulation and
cytolysis [56]. Further studies are thus required to eluci-
date the mechanism(s) by which NO influences the eosi-
nophil degranulation.
Conclusion
In summary, our study shows that the CC-chemokines
eotaxin and RANTES increases the in vitro eosinophil
adhesion and degranulation by NO-independent mecha-
nisms. The failure of CC-chemokine to affect VLA-4 and
Mac-1 expression on eosinophil surface indicates that
changes in the integrin function (avidity or affinity) are
rather involved in the enhanced adhesion.
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